Harnessing Bioinformatic Approaches to Designing a Multi-epitope Peptide Vaccine Against COVID-۱۹

Publish Year: 1400
نوع سند: مقاله کنفرانسی
زبان: English
View: 107

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

IBIS10_221

تاریخ نمایه سازی: 5 تیر 1401

Abstract:

Introduction: SARS-CoV-۲ is the causative agent of Coronavirus ۲۰۱۹ or COVID-۱۹ in the world. Novelcoronavirus disease is a respiratory disease. To date, there have been challenges in the treatment for COVID-۱۹ and emerged new variants. Accordingly, an effective prevention regime is needed for this infection, whichcovers most variants. The purpose of this research was to predict the conserved epitopes of Spike andNucleocapsid proteins from SARS-CoV-۲ for the design of a novel coronavirus ۲۰۱۹ multi-epitope vaccineusing in silico tools.Methods: Computational analysis and immunoinformatics approaches include identification of potentialconserve epitopes and selection of epitopes based on allergenicity, toxicity, antigenicity, and moleculardocking were used for epitope prediction and screening. In the next step, selected segments of the epitopeswere attached by the suitable linkers. Finally, Maltese-bound protein (MBP) as an adjuvant was added to thenovel vaccine structure. The secondary and third structures of the designed multi-epitope vaccine werepredicted via immunoinformatics algorithms. Predicted structure refined and validated for attaining beststability. In the end, immunoinformatics evaluation, molecular docking, and molecular dynamics wereperformed to confirm vaccine efficiency. Codon optimization and in silico cloning were done to ensure theexpression yield of the novel multi-epitope vaccine in the target host.Results: This study showed that our data support the suggestion that the designed vaccine could induceimmune responses against SARS-CoV-۲ variants.Conclusion: The Structure designed had acceptable quality with software reviews. Further in vitro and invivo experiments.

Authors

Tooba Ahmadi

Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

Vajihe Ghorbanzade

Cardiovascular Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran

Hassan Dariushnejad

Cardiovascular Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran- Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran